Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy

Brain, Behavior, and Immunity

Volumn 26, Issue 5, 2012, Pages 706-713

  Liu, Lianqi ^a   Mills, Paul J ^a,b,c   Rissling, Michelle ^a,b   Fiorentino, Lavinia ^a,c   Natarajan, Loki ^b,c   Dimsdale, Joel E ^a,b,c   Sadler, Georgia Robins ^c,d   Parker, Barbara A ^c,e   Ancoli Israel, Sonia ^a,b,c,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Breast cancer; Chemotherapy; Fatigue; Inflammatory markers; Sleep

Indexed keywords

C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; PACLITAXEL;

ACTIMETRY; ADULT; AGED; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE SEVERITY; FATIGUE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTIDIMENSIONAL FATIGUE SYMPTOM INVENTORY SHORT FORM; MULTIPLE CYCLE TREATMENT; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; REVIEW; SLEEP QUALITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; C-REACTIVE PROTEIN; CYTOKINES; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; FATIGUE; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; LONGITUDINAL STUDIES; MIDDLE AGED; MOTOR ACTIVITY; SLEEP; SLEEP DISORDERS;

EID: 84862796085     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.02.001     Document Type: Review

References (46)

1. Allgayer H., Nicolaus S., Schreiber S. Decreased interleukin-1 receptor antagonist response following moderate exercise in patients with colorectal carcinoma after primary treatment. Cancer Detect. Prev. 2004, 28:208-213.
2. Ancoli-Israel S., Cole R., Alessi C.A., Chambers M., Moorcroft W.H., Pollak C. The role of actigraphy in the study of sleep and circadian rhythms. Sleep 2003, 26:342-392.
3. Ancoli-Israel S., Liu L., Marler M., Parker B.A., Jones V., Robins Sadler G., Dimsdale J.E., Cohen-Zion M., Fiorentino L. Fatigue, sleep and circadian rhythms prior to chemotherapy for breast cancer. Support. Care Cancer 2006, 14:201-209.
4. Ancoli-Israel S., Moore P., Jones V. The relationship between fatigue and sleep in cancer patients: a review. Eur. J. Cancer Care (Engl) 2001, 10:245-255.
5. Aouizerat B.E., Dodd M., Lee K., West C., Paul S.M., Cooper B.A., Wara W., Swift P., Dunn L.B., Miaskowski C. Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. Biol. Res. Nurs. 2009, 11:27-41.
6. Bardwell W.A., Ancoli-Israel S. Breast cancer and fatigue. Sleep Med. Clin. 2008, 3:61-71.
7. Berger A.M., Parker K.P., Young-McCaughan S., Mallory G.A., Barsevick A.M., Beck S.L., Carpenter J.S., Carter P.A., Farr L.A., Hinds P.S., Lee K.A., Miaskowski C., Mock V., Payne J.K., Hall M. Sleep wake disturbances in people with cancer and their caregivers: state of the science. Oncol. Nurs. Forum 2005, 32:E98-E126.
8. Bower J.E., Ganz P., Aziz N., Fahey J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 2002, 64:604-611.
9. Bower J.E., Ganz P., Irwin M.R., Kwan L., Breen E.C., Cole S.W. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?. J. Clin. Oncol. 2011, 29:3517-3522.
10. Buysse D.J., Reynolds C.F.I., Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28:193-213.
11. Collado-Hidalgo A., Bower J.E., Ganz P.A., Cole S.W., Irwin M.R. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin. Cancer Res. 2006, 12:2759-2766.
12. Collado-Hidalgo A., Bower J.E., Ganz P.A., Irwin M.R., Cole S.W. Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings. Brain Behav. Immun. 2008, 22:1197-1200.
13. Denecker N.E., Kullberg B.J., Drenth J.P., Raemaekers J.M., van der Meer J.W. Regulation of the production of pro-inflammatory cytokines and antagonists during chemotherapy-induced neutropenia in patients with haematological malignancies. Cytokine 1997, 9:702-710.
14. Diggle P.J., Liang K.Y., Zeger S.L. Analysis of Longitudinal Data 1994, Oxford University Press, New York, NY.
15. Haku T., Yanagawa H., Ohmoto Y., Takeuchi E., Yano S., Hanibuchi M., Nokihara H., Nishimura N., Sone S. Systemic chemotherapy alters interleukin-1 beta and its receptor antagonist production by human alveolar macrophages in lung cancer patients. Oncol. Res. 1996, 8:519-526.
16. Hofman M., Ryan J.L., Figueroa-Moseley C.D., Jean-Pierre P., Morrow G.R. Cancer-related fatigue: the scale of the problem. Oncologist 2007, 12(Suppl 1):4-10.
17. Irwin M.R., Wang M., Campomayor C.O., Collado-Hidalgo A., Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch. Intern. Med. 2006, 166:1756-1762.
18. Kelley K.W., Bluthe R.-M., Dantzer R., Zhou J.-H., Shen W.-H., Johnson R.W., Broussard S.R. Cytokine-induced sickness behavior. Brain Behav. Immun. 2003, 17:S112-S118.
19. Knupfer H., Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res. Treat. 2007, 102:129-135.
20. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001, 92:1684-1688.
21. Lee B.N., Dantzer R., Langley K.E., Bennett G.J., Dougherty P.M., Dunn A.J., Meyers C.A., Miller A.H., Payne R., Reuben J.M., Wang X.S., Cleeland C.S. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. NeuroImmunoModulation 2004, 11:279-292.
22. Liu L., Ancoli-Israel S. Sleep disturbances in cancer. Psychiatry Ann. 2008, 38:627-634.
23. Liu L., Marler M., Parker B.A., Jones V., Johnson S., Cohen-Zion M., Fiorentino L., Sadler G.R., Ancoli-Israel S. The relationship between fatigue and light exposure during chemotherapy. Support. Care Cancer 2005, 13:1010-1017.
24. Liu L., Rissling M., Natajaran L., Fiorentino L., Mills P.J., Dimsdale J.E., Sadler G.R., Parker B.A., Ancoli-Israel S. The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy. Sleep 2012, 35:237-245.
25. Miaskowski C., Dodd M., Lee K., West C., Paul S.M., Cooper B.A., Wara W., Swift P.S., Dunn L.B., Aouizerat B.E. Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers. J. Pain Symptom Manage. 2010, 40:531-544.
26. Miller A.H., Ancoli-Israel S., Bower J.E., Capuron L., Irwin M.R. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J. Clin. Oncol. 2008, 26:971-982.
27. Miller L.J., Kurtzman S.H., Anderson K., Wang Y., Stankus M., Renna M., Lindquist R., Barrows G., Kreutzer D.L. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest. 2000, 18:293-302.
28. Miller R.G. Simultaneous Statistical Inference, Springer Series in Statistics 1981, Springer-Verlag, New York, NY. Second ed.
29. Mills P.J., Ancoli-Israel S., Parker B.A., Natarajan L., Hong S., Jain S., Sadler G.R., von Kanel R. Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer. Brain Behav. Immun. 2008, 22:98-104.
30. Mills P.J., Parker B.A., Dimsdale J.E., Sadler G.R., Ancoli-Israel S. The relationship between fatigue, quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biol. Psychol. 2005, 69:85-96.
31. Mills P.J., Parker B.A., Jones V., Adler K.A., Perez C.J., Johnson S., Cohen-Zion M., Marler M.R., Sadler G.R., Dimsdale J.E., Ancoli-Israel S. The effects of standard anthracycline-based chemotherapy on soluble icam-1 and VEFG levels in breast cancer. Clin. Cancer Res. 2004, 10:4998-5003.
32. O'Hanlon D.M., Fitzsimons H., Lynch J., Tormey S., Malone C., Given H.F. Soluble adhesion molecules (E_selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur. J. Cancer 2002, 38:2252-2257.
33. Opp M.R. Cytokines and sleep. Sleep Med. Rev. 2005, 9:355-364.
34. Raison C.L., Rye D.B., Woolwine B.J., Vogt G.J., Bautista B.M., Spivey J.R., Miller A.H. Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol. Psychiatry 2010, 68:942-949.
35. Ravishankaran P., Karunanithi R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg. Oncol. 2011, 9:18.
36. Rich T., Innominato P.F., Boerner J., Iacobelli S., Baron B., Jasmin C., Levi F. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin. Cancer Res. 2005, 11:1757-1764.
37. Roscoe J.A., Kaufman M.E., Matteson-Rusby S.E., Palesh O.G., Ryan J.L., Kohli S., Perlis M.L., Morrow G.R. Cancer-related fatigue and sleep disorders. Oncologist 2007, 12(Suppl 1):35-42.
38. Schubert C., Hong S., Natarajan L., Mills P.J., Dimsdale J.E. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav. Immun. 2007, 21:413-427.
39. Slattery M.L., Curtin K., Baumgartner R., Sweeney C., Byers T., Giuliano A.R., Baumgartner K.B., Wolff R.R. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol. Biomarkers Prev. 2007, 16:747-755.
40. Soules M.R., Sherman S., Parrott E., Rebar R., Santoro N., Utian W., Woods N. Executive summary: stages of reproductive aging workshop (STRAW) Park City, Utah, July, 2001. Menopause 2001, 8:402-407.
41. Stein K.D., Jacobsen P.B., Blanchard C.M., Thors C. Further validation of the multidimensional fatigue symptom inventory-short form. J. Pain Symptom Manage. 2004, 27:14-23.
42. Stein K.D., Martin S.C., Hann D.M., Jacobsen P.B. A multidimensional measure of fatigue for use with cancer patients. Cancer Pract. 1998, 6:143-152.
43. Vgontzas A.N., Papanicolaou D.A., Bixler E.O., Kales A., Tyson K., Chrousos G. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J. Clin. Endocrinol. Metab. 1997, 82:1313-1316.
44. Vgontzas A.N., Zoumakis E., Bixler E.O., Lin H.M., Follett H., Kales A., Chrousos G.P. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J. Clin. Endocrinol. Metab. 2004, 89:2119-2126.
45. Wang X.S., Shi Q., Williams L.A., Mao L., Cleeland C.S., Komaki R.R., Mobley G.M., Liao Z. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav. Immunity 2010, 24:968-974.
46. Zee P.C., Ancoli-Israel S. Does effective management of sleep disorders reduce cancer-related fatigue?. Drugs 2009, 69:29-41.